Contact Us marketing@medicilon.com
CN
×
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button

ContainCD73Content

Dec 29,2023
Medicilon Interview with Dr. Yifan Zhan | CD73 targeted therapy has ushered in a new dawn, revealing the research history and future prospects of Huaota Biopharmaceutical
In the field of immunotherapy, CD73, an immune regulatory molecule, has attracted much attention in recent years. Medicilon had the honor to interview Dr. Yifan Zhan, Chief Scientist of Huaota.
More
Medicilon Interview with Dr. Yifan Zhan | CD73 targeted therapy has ushered in a new dawn, revealing the research history and future prospects of Huaota Biopharmaceutical
Nov 22,2023
Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US
Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 developed by the company targeting the CD73 antigen will enter clinical trials. This is the first antibody conjugate drug project approved by Huaota Biotech to enter clinical trials by the FDA.
More
Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US